Viread takes on Baraclude

Published: 2013-08-20 06:58:00

Updated: 2013-08-20 06:58:00

Yuhan Corp. is enjoying brisk sales of its new anti-hepatitis B drug, Viread (tenofovir) developed by Gilead Sciences as a nucleotide reverse transcriptase inhibitor.

According to IMS data, sales of Viread reached over 17 billion won since its coverage by national health insurance in December ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK